Jim Kastenmayer
General Counsel at ARRIVENT BIOPHARMA, INC.
Net worth: 131 914 $ as of 2024-03-30
Profile
Jim Kastenmayer is currently the Secretary & General Counsel at Arrivent BioPharma, Inc. He previously worked as the Legal Director & Senior Patent Director at AstraZeneca PLC from 2012 to 2019.
He also worked as the Secretary & General Counsel at Spyre Therapeutics, Inc. from 2021 to 2023 and at Viela Bio, Inc. from 2020 to 2021.
Additionally, he worked as an IP Counsel at Medimmune, Inc. Dr. Kastenmayer holds a doctorate degree from Michigan State University, an undergraduate degree from the University of Virginia, and a graduate degree from Georgetown University Law Center.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ARRIVENT BIOPHARMA, INC.
0.02% | 2024-01-24 | 7,386 ( 0.02% ) | 131 914 $ | 2024-03-30 |
Jim Kastenmayer active positions
| Companies | Position | Start |
|---|---|---|
| ARRIVENT BIOPHARMA, INC. | General Counsel | 2023-08-31 |
Former positions of Jim Kastenmayer
| Companies | Position | End |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Chief Executive Officer | 2022-11-28 |
| VIELA BIO, INC. | General Counsel | 2021-02-28 |
| ASTRAZENECA PLC | General Counsel | 2019-11-30 |
| Medimmune, Inc. | Corporate Officer/Principal | - |
Training of Jim Kastenmayer
| Michigan State University | Doctorate Degree |
| University of Virginia | Undergraduate Degree |
| Georgetown University Law Center | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| SPYRE THERAPEUTICS, INC. | Health Technology |
| ARRIVENT BIOPHARMA, INC. | Health Technology |
| Private companies | 2 |
|---|---|
| Medimmune, Inc. | Health Technology |
Viela Bio, Inc.
 Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
- Stock Market
- Insiders
- Jim Kastenmayer